top of page

CiPA, the Comprehensive In Vitro Proarrythmia Assay, is a new paradigm for drugs' pre-clinical cardiac safety assessment, initiated and developed with global efforts (

DRIVEN by a suite of mechanistically based in vitro assays coupled to in silico reconstructions of cellular cardiac ion channel electrophysiologic activity, CiPA assay will inform the potential proarrhythmia risk of a test substance and contribute to the design of clinical drug safety study.


the science2_website_12092021.tif
the science2_website_12092021.tif
bottom of page